BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

...EGFR2; ErbB2; neu) HpV16gp1 - E6 transforming protein of HPV type 16 virus HpV16gp2 - E7 transforming protein...
BioCentury | Mar 27, 2019
Financial News

Elicio raises $30M to target cancer vaccines to the lymph nodes

...of biological engineering at MIT. Targets: E6 transforming protein (Human papillomavirus-16) - HpV16gp1; E7 transforming protein (Human papillomavirus-16) - HpV16gp2...
...HpV16gp2; KRAS - K-Ras Mary Romeo, Staff Writer Massachusetts Institute of Technology E6 transforming protein (Human papillomavirus-16) (HpV16gp1) E7 transforming protein (Human papillomavirus-16) (HpV16gp2) K-Ras...
BioCentury | Jan 4, 2019
Financial News

Cellid proposes Korean IPO

...BVAC-C, a B cell vaccine based on E6 transforming protein (human papillomavirus-16; HpV16gp1), E7 transforming protein (human papillomavirus-18; HpV18gp2), HpV16gp2...
...underwriting the IPO. Cellid Co. Ltd., Seoul, South Korea Chris Lieu BVAC-C Cellid Inc. E6 transforming protein (Human papillomavirus-16) (HpV16gp1) E7 transforming protein (Human papillomavirus-18) (HpV18gp2)...
BioCentury | Nov 9, 2018
Company News

Cue, LG in biologics deal

...is an IL-2 costimulatory factor linked to a T cell receptor targeting E6 transforming protein (human papillomavirus-18...
...Ltd. (KRX:051910), Seoul, South Korea Business: Cancer Elizabeth S. Eaton CUE-101 Cue Biopharma Inc. LG Chem Ltd. E6 transforming protein (Human papillomavirus-18...
BioCentury | Oct 31, 2018
Distillery Therapeutics

Cancer; infectious disease

...mouse models of ovalbumin-expressing melanoma and human papillomavirus (HPV)-associated cervical cancer, immunization with ovalbumin/simvastatin or E7 transforming protein/simvastatin...
...for acute coronary syndrome, dyslipidemia, hypercholesterolemia, hyperlipidemia and to prevent cardiovascular events. TARGET/MARKER/PATHWAY: E7 transforming protein (Human papillomavirus-16; HpV16gp2...
...Beijing, China email: yanshi@biomed.tsinghua.edu.cn CONTACT: Yonghui Zhang, same affiliation as above email: zhangyonghui@tsinghua.edu.cn Mark Zipkin Zocor, simvastatin Tsinghua University E7 transforming protein (Human papillomavirus-16) (HpV16gp2) Cancer...
BioCentury | Sep 26, 2018
Distillery Therapeutics

Cancer

...cell line resistant to immunotherapy, radiotherapy and chemotherapy and treated with cytotoxic T lymphocytes targeting HpV16gp2...
...formation of tumor spheres. In a mouse model of lung cancer, N-acetyl cysteine plus the HpV16gp2-targeting...
...other T cell therapy- or chemotherapy-resistant cancers. TARGET/MARKER/PATHWAY: ATP synthase peripheral stalk subunit d (ATP5H); E7 transforming protein (Human papillomavirus-16) (HpV16gp2)...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Cancer

...INDICATION: Cervical cancer; skin cancer Mouse studies suggest a vaccine based on a nanoparticle-HpV16gp2 peptide conjugate...
...human papillomavirus (HPV)-associated cancers. The conjugate consists of nanoparticles with a polypropylene sulfide core and HpV16gp2...
...cancer, solid tumors and HPV and Phase I/II testing for cervical cancer. TARGET/MARKER/PATHWAY: E7 transforming protein (Human papillomavirus-16; HpV16gp2...
BioCentury | Jul 13, 2018
Clinical News

Vaxart's teslexivir misses in Phase II for anogenital warts

Vaxart Inc. (NASDAQ:VXRT) said twice-daily topical teslexivir (BTA074) 5% gel missed the primary endpoint of improving the complete clearance rate of baseline anogenital warts (condyloma) by week 16 vs. placebo in a Phase II trial...
BioCentury | Jul 13, 2018
Clinical News

FDA lifts hold on Phase I/II of axalimogene filolisbac for SCCHN

...and neck (SCCHN). Axalimogene filolisbac is a live Listeria monocytogenes -based immunotherapy expressing E7 transforming protein (human papillomavirus-16; HpV16gp2...
...filolisbac (ADXS11-001) (formerly Lovaxin C, ADXS-HPV) Business: Cancer Jaime De Leon Axalimogene filolisbac (ADXS11-001, adxs-hpv, lovaxin c) Advaxis Inc. E7 transforming protein (Human papillomavirus-16) (HpV16gp2)...
BioCentury | Jul 13, 2018
Clinical News

Advaxis rises after FDA lifts clinical hold

...and neck (SCCHN). Axalimogene filolisbac is a live Listeria monocytogenes -based immunotherapy expressing E7 transforming protein (human papillomavirus-16; HpV16gp2...
...drug also has accelerated approval to treat urothelial carcinoma. Paul Bonanos Axalimogene filolisbac (ADXS11-001, adxs-hpv, lovaxin c) Advaxis Inc. E7 transforming protein (Human papillomavirus-16) (HpV16gp2)...
Items per page:
1 - 10 of 78